CRISPR Therapeutics : Regulation FD Presentation - Form 8-K

a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, cell and... | April 3, 2023

Related Keywords

United States , Australia , Massachusetts , United Kingdom , San Francisco , California , Boston , Cambridge , Cambridgeshire , Switzerland , London , City Of , America , American , Rachel Eides , Susie Lisa , Carmen Bozic , Manisha Pai , Miroslava Minkova , Heather Nichols , Phuong Khanh , Susan Kim , Therapeutics Inc , European Commission , Vertex Pharmaceuticals Incorporated , Exchange Commission , Linkedin , Instagram , Twitter , Vertex Pharmaceuticals , Vertex Pharmaceuticals Incorporated Nasdaq , European Medicines Agency , Viacyte Inc , American Society Of Hematology , Youtube , Global Medicines Development , Facebook , Regulatory Agency , Drug Administration , Complete Submission , Rolling Biologics License Applications , Sickle Cell Disease , Transfusion Dependent Beta Thalassemia , Pharmaceuticals Incorporated , Biologics License Applications , Priority Review , American Society , Annual Meeting , Executive Vice President , Medical Affairs , Chief Medical Officer , Regenerative Medicine Advanced Therapy , Fast Track , Orphan Drug , Rare Pediatric Disease , Marketing Authorization Applications , Orphan Drug Designation , Priority Medicines , Innovation Passport , Innovative Licensing , Access Pathway , New England Journal , Gene Editing Process , These Trials , Innovation District , North America , Top Employers , Best Workplaces , Private Securities Litigation Reform Act , While Vertex , Forward Looking Statement , Crispr Therapeutics Ag Stock Exchange , News , Information , Press Release , , Enetic , Disease , End , Gas , Several , Ngoing , Linical , Research , Programs , N , Beyond , Vertex , Obust , Pipeline , F , Investigational , Mall , Ell Crsp Ch0334081137 ,